BTG posts 19pc revenue jump

 
Suzie Neuwirth

HEALTHCARE company BTG today announced a 19 per cent increase in revenues, thanks to a strong performance in speciality pharmaceuticals.

The firm reported pre-tax profits of £16.4m for the year, compared to £14.6m the previous year.

Specialist antidotes CroFab and DigiFab performed particularly well and a new cancer patient treatment Vorxaze was recently launched in the US.